Association of Proliferative Indices With Various Grades of Breast Carcinoma

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Aug 16

PMID 37583729

Authors

Seema Awasthi

Pooja Gupta

Ankita Mittal

Affiliations

Soon will be listed here.

Abstract

Aims And Objectives: Various grades of breast carcinoma and proliferative indices used as nuclear protein Ki-67 and argyrophilic nucleolar organizer regions (AgNOR) are being compared to each other.

Materials And Method: In this observational cross-sectional investigation, 42 breast biopsies from questionable breast areas were collected and preserved in formalin and paraffin before the tissue blocks were made. A thorough medical history regarding the breast tumor and thorough physical examination results were recorded. Two sections were produced, one stained with an immunohistochemical marker called Ki-67 and the other with a unique stain called AgNOR.

Results: Grade I in Nottingham was found to be highest in subjects with Ki-67 1%, grade II in subjects with Ki-67 1-10%, and grade III in subjects with Ki-67>10%. Therefore, a higher Ki-67 score and a higher Nottingham grade were more closely associated. The mean AgNOR score was determined to be highest in Nottingham grade III and lowest in Nottingham grade I. In contrast to grade I and grade II of carcinoma (CA) breast, where there was no statistically significant association between Ki-67 and AgNOR, grade III of CA breast showed a statistically significant link between Ki-67 and AgNOR.

Conclusion: Proliferation has been identified as a distinctive feature of cancer and as a key factor in the prognosis of the disease.

Citing Articles

Retinoblastoma and polydactyly in a child with 46, XY, 15pstk+ karyotype-A case report and literature review.

Pi X, Zhang Q, Wang X, Jiang F Mol Genet Genomic Med. 2024; 12(3):e2414.

PMID: 38465842 PMC: 10926652. DOI: 10.1002/mgg3.2414.

References

Sotiriou C, Neo S, McShane L, Korn E, Long P, Jazaeri A . Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100(18):10393-8. PMC: 193572. DOI: 10.1073/pnas.1732912100. View

Shukla S, Acharya S, Vagha S, Dawande P, Tamhane A . Role of Immunophenotypes in Carcinoma Breast. Int J Appl Basic Med Res. 2019; 8(4):210-216. PMC: 6259294. DOI: 10.4103/ijabmr.IJABMR_331_17. View

Dube M, Govil A . Evaluation of significance of AgNOR counts in differentiating benign from malignant lesions in the breast. Indian J Pathol Microbiol. 1995; 38(1):5-10. View

Park D, Karesen R, Noren T, Sauer T . Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch. 2007; 451(1):11-8. DOI: 10.1007/s00428-007-0435-2. View

Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S . Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res. 2003; 6(1):R24-30. PMC: 314452. DOI: 10.1186/bcr738. View

Stathopoulos G, Malamos N, Markopoulos C, Polychronis A, Armakolas A, Rigatos S . The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anticancer Drugs. 2014; 25(8):950-7. PMC: 4162382. DOI: 10.1097/CAD.0000000000000123. View

Li L, Jiang G, Chen Q, Zheng J . Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2014; 11(3):1566-72. DOI: 10.3892/mmr.2014.2914. View

Vargo-Gogola T, Rosen J . Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007; 7(9):659-72. DOI: 10.1038/nrc2193. View

Goyal R, Mohi K, Bal Singh M . AgNOR Count and its Correlation with Colposcopy in Suspicious Cervix. J Obstet Gynaecol India. 2013; 62(4):437-41. PMC: 3500951. DOI: 10.1007/s13224-012-0300-3. View

10.

Wojnar A, Kobierzycki C, Krolicka A, Pula B, Podhorska-Okolow M, Dziegiel P . Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. Folia Histochem Cytobiol. 2010; 48(3):442-6. DOI: 10.2478/v10042-010-0069-0. View

11.

Kunc M, Biernat W, Senkus-Konefka E . Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?. Cancer Treat Rev. 2018; 67:78-87. DOI: 10.1016/j.ctrv.2018.05.005. View

12.

Ansari R, Craze M, Althobiti M, Alfarsi L, Ellis I, Rakha E . Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. Br J Cancer. 2019; 122(1):94-101. PMC: 6964696. DOI: 10.1038/s41416-019-0626-z. View

13.

Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A . Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2008; 20(4):628-35. DOI: 10.1093/annonc/mdn675. View

14.

de Azambuja E, Cardoso F, de Castro Jr G, Colozza M, Mano M, Durbecq V . Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007; 96(10):1504-13. PMC: 2359936. DOI: 10.1038/sj.bjc.6603756. View

15.

Reis-Filho J, Lakhani S . Breast cancer special types: why bother?. J Pathol. 2008; 216(4):394-8. DOI: 10.1002/path.2419. View

16.

Cheang M, Martin M, Nielsen T, Prat A, Voduc D, Rodriguez-Lescure A . Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist. 2015; 20(5):474-82. PMC: 4425383. DOI: 10.1634/theoncologist.2014-0372. View

17.

Setyawati Y, Rahmawati Y, Widodo I, Ghozali A, Purnomosari D . The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman. Asian Pac J Cancer Prev. 2018; 19(5):1263-1268. PMC: 6031822. DOI: 10.22034/APJCP.2018.19.5.1263. View